




CORPORATE PROFILE

Seikagaku Corporation is a leader in the expanding field of glycoscience, a discipline that involves the study of glycoconjugates—complex, hybrid macromolecules of carbohydrate and non-carbohydrate composition that serve to control all of life’s basic processes. In 1950, Seikagaku was the first company to manufacture chondroitin sulfate on an industrial scale, and this substance is now an essential component of a wide variety of pharmaceutical products. In 1987, it launched the world’s first sodium hyaluronate formulation for osteoarthritis in knee and shoulder joints, which it sells under the ARTZ®, ARTZAL® and SUPARTZ® brands throughout the world.

Today, Seikagaku is recognized internationally as a primary producer of glycoconjugate-related pharmaceuticals, such as sodium hyaluronate formulations for osteoarthritis, along with OPEGAN® and OPEGAN Hi®, which were Japan’s first sodium hyaluronate formulations for use as surgical aids in cataract surgery.

Seikagaku’s business focuses on the area of ethical pharmaceuticals, along with research biologicals and diagnostics that are used for glycoconjugate research and medical treatment. The sale of pharmaceutical bulk products also comprises a significant portion of Seikagaku’s operations.

Seikagaku’s Business Outline



Seikagaku pioneered glycoscience research over 50 years ago. Our mission is to improve quality of life by creating safe, functionally unique and useful products for the world based on leading-edge fundamental and clinical research centered on glycoscience.

Contents

Glycoscience	1
R&D Activities	2
Consolidated Financial Highlights	5
A Message from the President	6
Divisional Review	8
Organization	9
Financial Statements	10
Corporate Data	21